(The study of of 1,879 adults with Type 2 diabetes was funded by Eli Lilly.) With this new class of medication, we are reaching levels of efficacy that are really unprecedented, said Mathilde Merlet, Eli Lillys general manager for Canada
Discussion This study provided a novel perspective on exploring the association between GLP-1 RAs and mood disorders using publicly accessible databases
The primary efficacy parameter was mean percent change in BMI from baseline after 52 weeks on a therapeutic regimen of setmelanotide compared to placebo
Gschl L, Scheinecker C, Bonelli M
org/10.1002/14651858.CD009374.pub3 Dahash, B
They will work with you to make the medication changes safely Our goal is not to have you on semaglutide or other medications forever